AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4596491 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent El Tor vaccines (not specified)
Number of subjects: 0
Study 4596491 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent classical Inaba vaccine
Number of subjects: 0
Study 31520613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancolonic chromoendoscopy (n = 128)
Number of subjects: 256
Study 31520613 — intervention group
Group type: COMPARATOR
Intervention: High-definition white-light endoscopy (n = 128)
Number of subjects: 256
Study 30953333 — intervention group
Group type: EXPERIMENTAL
Intervention: roxadustat 50 mg TIW
Number of subjects: 107
Study 30953333 — intervention group
Group type: EXPERIMENTAL
Intervention: roxadustat 70 mg TIW
Number of subjects: 107
Study 30953333 — intervention group
Group type: EXPERIMENTAL
Intervention: roxadustat 100 mg TIW
Number of subjects: 107
Study 30953333 — intervention group
Group type: EXPERIMENTAL
Intervention: roxadustat TIW
Number of subjects: 107
Study 30953333 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study 28726169 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine mucoadhesive buccal tablet (MBT) 50 and 100 µg
Number of subjects: 36
Study 28726169 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine mucoadhesive buccal tablet (MBT)
Number of subjects: 36
Study 28726169 — intervention group
Group type: COMPARATOR
Intervention: Reference clonidine oral tablet (OT)
Number of subjects: 36
Study 26067732 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoAg‐IS‐BOA
Number of subjects: 24
Study 26067732 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoAg‐I‐BOA
Number of subjects: 24
Study 26067732 — intervention group
Group type: COMPARATOR
Intervention: Control BOA (standard PMMA)
Number of subjects: 24
Study 23769414 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (HF-rTMS)
Number of subjects: 21
Study 23769414 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 21
Study 22090050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl (absorbable sutures)
Number of subjects: 38
Study 22090050 — intervention group
Group type: COMPARATOR
Intervention: Nylon (nonabsorbable sutures)
Number of subjects: 38
Study 19339887 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent advancements in RCC treatments
Number of subjects: 0
Study 19339887 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly based biomarker studies
Number of subjects: 0
Study 19339887 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prognostic factors
Number of subjects: 0
Study 16510545 — intervention group
Group type: COMPARATOR
Intervention: Serum enterolactone concentration (measured by gas chromatography-mass spectrometry)
Number of subjects: 340
Study 16510545 — intervention group
Group type: COMPARATOR
Intervention: Highest quintile of serum enterolactone
Number of subjects: 340
Study 15569790 — intervention group
Group type: EXPERIMENTAL
Intervention: benznidazole
Number of subjects: 0
Study 11329233 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - conjugated estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 5 mg/d for 13 days, for 9 months
Number of subjects: 59
Study 9416890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure measurement (sphygmomanometry)
Number of subjects: 2231
Study 9416890 — intervention group
Group type: COMPARATOR
Intervention: Captopril or placebo (treatment arm)
Number of subjects: 2231
Study 8495311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin, 500 mg every 8 hours for 24 hours
Number of subjects: 113
Study 8495311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 8495311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 113
Study 3122113 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 40
Study 3122113 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis
Number of subjects: 40
Study 3122113 — intervention group
Group type: COMPARATOR
Intervention: Modified Goeckerman treatment
Number of subjects: 40
Study 29497290 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV
Number of subjects: 60
Study 29497290 — intervention group
Group type: EXPERIMENTAL
Intervention: HFCWO
Number of subjects: 60
Study 29497290 — intervention group
Group type: COMPARATOR
Intervention: PT alone
Number of subjects: 60
Study 27179440 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-0 Vicryl
Number of subjects: 871
Study 27179440 — intervention group
Group type: COMPARATOR
Intervention: 4-0 Monocryl
Number of subjects: 871
Study 24112944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for BRVO
Number of subjects: 66
Study 24112944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for CRVO
Number of subjects: 66
Study 24112944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab plus scatter photocoagulation for BRVO and CRVO
Number of subjects: 66
Study 22203758 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care integrated with standard oncology care
Number of subjects: 151
Study 22203758 — intervention group
Group type: COMPARATOR
Intervention: Standard oncology care alone
Number of subjects: 151
Study 20531012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 2971
Study 20531012 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 2971
Study 18185135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician grading of diabetic retinopathy severity
Number of subjects: 118
Study 18185135 — intervention group
Group type: COMPARATOR
Intervention: Reading center (RC) grading of diabetic retinopathy severity
Number of subjects: 118
Study 15906123 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 6 mg
Number of subjects: 451
Study 15906123 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg
Number of subjects: 451
Study 15906123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 12508388 — intervention group
Group type: EXPERIMENTAL
Intervention: IV doxycycline 300 mg/day for 14 days
Number of subjects: 23
Study 12508388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10533691 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive discharge planning and home follow-up by an advanced practice nurse (APN) for 4 weeks after discharge
Number of subjects: 202
Study 10533691 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 202
Study 8952749 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for prevention and treatment of bone loss in lupus patients; specific interventions not detailed.
Number of subjects: 0
Study 8952749 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of steroid-induced bone loss; specific interventions not detailed.
Number of subjects: 0
Study 8952749 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of gonadal effects of cytotoxic agents; specific interventions not detailed.
Number of subjects: 0
Study 1951568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sadovsky fetal movement counting (n = 63)
Number of subjects: 213
Study 1951568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiff fetal movement counting (n = 62)
Number of subjects: 213
Study 1951568 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 88)
Number of subjects: 213
Study 7009424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 12
Study 7009424 — intervention group
Group type: EXPERIMENTAL
Intervention: Time (during study period)
Number of subjects: 12
Study 7009424 — intervention group
Group type: EXPERIMENTAL
Intervention: Time (during outpatient period)
Number of subjects: 12
Study 7009424 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study 30869820 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy with a written checklist (Group II)
Number of subjects: 155
Study 30869820 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with a written checklist (Group IV)
Number of subjects: 155
Study 30869820 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment plus behavioral therapy without a checklist (Group III)
Number of subjects: 155
Study 30869820 — intervention group
Group type: COMPARATOR
Intervention: Behavioral therapy as a written guideline (Group I)
Number of subjects: 155
Study 28003539 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg daily from 18-22 weeks of gestation to delivery)
Number of subjects: 524
Study 28003539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study 24985364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain diary group
Number of subjects: 58
Study 24985364 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 24037492 — intervention group
Group type: COMPARATOR
Intervention: TLSO (closed)
Number of subjects: 20
Study 24037492 — intervention group
Group type: EXPERIMENTAL
Intervention: TLSO (open)
Number of subjects: 20
Study 22926666 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change (loss or gain) over 4 years
Number of subjects: 1826
Study 22926666 — intervention group
Group type: COMPARATOR
Intervention: Stable weight (weight change < 5 lb)
Number of subjects: 1826
Study 22926666 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg/m²)
Number of subjects: 1826
Study 19954716 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide/metformin combination tablet (80/500 mg)
Number of subjects: 32
Study 19954716 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of gliclazide (80 mg) and metformin (500 mg) as individual tablets
Number of subjects: 32
Study 17355215 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel compounds under investigation for heart failure treatment
Number of subjects: 0
Study 15825717 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tropicamide and 10% phenylephrine
Number of subjects: 564
Study 15825717 — intervention group
Group type: COMPARATOR
Intervention: 1% tropicamide and 2.5% phenylephrine
Number of subjects: 564
Study 15388907 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude bullrout venom
Number of subjects: 0
Study 15388907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocitoxin
Number of subjects: 0
Study 15388907 — intervention group
Group type: COMPARATOR
Intervention: Negative controls (pooled nonalgesic proteins)
Number of subjects: 0
Study 10490152 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine with 0.3 mg epinephrine (EPI group)
Number of subjects: 62
Study 10490152 — intervention group
Group type: COMPARATOR
Intervention: Procaine with 0.3 ml NaCl 0.9% (SALINE group)
Number of subjects: 62
Study 10490152 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (EPI group)
Number of subjects: 62
Study 8944409 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg with fluvoxamine (mean dose 127 mg/day)
Number of subjects: 11
Study 8944409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment
Number of subjects: 11
Study 8944409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1742482 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (1.0 microgram/kg/d, increased to 3.0, 5.0, and 10.0 micrograms/kg as needed)
Number of subjects: 17
Study 1742482 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF (1.0 microgram/kg/d, increased as needed) with full-dose zidovudine (1,200 mg/d)
Number of subjects: 17
Study 6896183 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol 100 mg
Number of subjects: 6
Study 6896183 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol 200 mg
Number of subjects: 6
Study 6896183 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 160 mg
Number of subjects: 6
Study 31198999 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide pneumococcal vaccination (23vPPV)
Number of subjects: 227
Study 31198999 — intervention group
Group type: COMPARATOR
Intervention: No 23vPPV
Number of subjects: 227
Study 31656454 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese soy sauce (Koikuchi Shoyu) exposure group
Number of subjects: 72
Study 31656454 — intervention group
Group type: COMPARATOR
Intervention: Phenylethyl alcohol (PEA) exposure group
Number of subjects: 72
Study 31656454 — intervention group
Group type: COMPARATOR
Intervention: Water exposure group
Number of subjects: 72
Study 30184451 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus lenalidomide
Number of subjects: 1030
Study 30184451 — intervention group
Group type: COMPARATOR
Intervention: Rituximab plus chemotherapy
Number of subjects: 1030
Study 26477496 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 10 mg daily ulipristal acetate for four repeated 12‐week treatment courses
Number of subjects: 451
Study 24249538 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography follow-up
Number of subjects: 500
Study 24249538 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan follow-up
Number of subjects: 500
Study 24249538 — intervention group
Group type: COMPARATOR
Intervention: 6-monthly follow-up
Number of subjects: 500
Study 24249538 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly follow-up
Number of subjects: 500
Study 23196436 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZP)
Number of subjects: 142
Study 23196436 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 142
Study 23196436 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 142
Study 20718807 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast protocol (increment: 2 w/6 s)
Number of subjects: 17
Study 20718807 — intervention group
Group type: COMPARATOR
Intervention: Slow protocol (increment: 1 w/6 s)
Number of subjects: 17
Study 17570469 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 608
Study 17570469 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 608
Study 17570469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 16014264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 24
Study 16014264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12010339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/day)
Number of subjects: 96
Study 12010339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 9885303 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin potassium
Number of subjects: 0
Study 9885303 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0
Study 9885303 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 0
Study 8580277 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole oral suspension (200 mg loading dose followed by 100 mg q.d.s. for 2 weeks after symptom resolution)
Number of subjects: 42
Study 8580277 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole oral suspension
Number of subjects: 42
Study 30967395 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 254
Study 30967395 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab with mycophenolate mofetil
Number of subjects: 254
Study 29747616 — intervention group
Group type: COMPARATOR
Intervention: RBP4 tertiles (highest vs lowest)
Number of subjects: 167
Study 29747616 — intervention group
Group type: COMPARATOR
Intervention: TTR tertiles (highest vs lowest)
Number of subjects: 167
Study 29747616 — intervention group
Group type: COMPARATOR
Intervention: HOMA-IR tertiles (highest vs lowest)
Number of subjects: 167
Study 29747616 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride levels
Number of subjects: 167
Study 29747616 — intervention group
Group type: EXPERIMENTAL
Intervention: TTR levels
Number of subjects: 167
Study 27529806 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 65
Study 27529806 — intervention group
Group type: EXPERIMENTAL
Intervention: Poetry
Number of subjects: 65
Study 27529806 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study 24742965 — intervention group
Group type: EXPERIMENTAL
Intervention: S-PC (Smoker Patient Control) tool
Number of subjects: 229
Study 24742965 — intervention group
Group type: COMPARATOR
Intervention: No S-PC tool
Number of subjects: 229
Study 22640531 — intervention group
Group type: EXPERIMENTAL
Intervention: Care pathway intervention including formative evaluation, evidence-based key interventions, and support for implementation.
Number of subjects: 437
Study 22640531 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm).
Number of subjects: 437
Study 19292590 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir monotherapy
Number of subjects: 0
Study 19292590 — intervention group
Group type: COMPARATOR
Intervention: efavirenz-based triple combination therapy
Number of subjects: 0
Study 17383296 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 2521
Study 17383296 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use in ischemic cardiomyopathy
Number of subjects: 2521
Study 17383296 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use in nonischemic cardiomyopathy
Number of subjects: 2521
Study 17383296 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use in patients with implantable cardioverter defibrillator (ICD)
Number of subjects: 2521
Study 17383296 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use in non-ICD patients
Number of subjects: 2521
Study 17383296 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use in New York Heart Association II patients
Number of subjects: 2521
Study 17383296 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use in New York Heart Association III patients
Number of subjects: 2521
Study 15486391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric collection tubes filled 100%
Number of subjects: 30
Study 15486391 — intervention group
Group type: COMPARATOR
Intervention: Pediatric collection tubes filled 50%
Number of subjects: 30
Study 11239184 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 624
Study 11239184 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 624
Study 11301568 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B complex capsules (fursulthiamine 50 mg, hydroxocobalamin 250 micrograms, pyridoxal phosphate 30 mg, and riboflavin 5 mg)
Number of subjects: 28
Study 11301568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7870400 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information
Number of subjects: 0
Study 7870400 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 0
Study 7870400 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional information)
Number of subjects: 0
Study 7870400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both experimental groups (verbal and written)
Number of subjects: 0
Study 3360270 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracentesis plus intravenous albumin infusion (40 g after each tap)
Number of subjects: 105
Study 3360270 — intervention group
Group type: COMPARATOR
Intervention: Paracentesis without intravenous albumin infusion
Number of subjects: 105
Study 31599692 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A1
Number of subjects: 90
Study 31599692 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Density Lipoprotein (HDL) cholesterol
Number of subjects: 90
Study 31599692 — intervention group
Group type: COMPARATOR
Intervention: Cytokines
Number of subjects: 90
Study 30049221 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference Interpretation (TI)
Number of subjects: 2
Study 29132458 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil+midazolam
Number of subjects: 80
Study 29132458 — intervention group
Group type: COMPARATOR
Intervention: midazolam
Number of subjects: 80
Study 29132458 — intervention group
Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 80
Study 26331821 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride 150 mg every 12 hours
Number of subjects: 30
Study 26331821 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride 200 mg every 12 hours
Number of subjects: 30
Study 26331821 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride 125 mg every 8 hours
Number of subjects: 30
Study 26331821 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride (various doses)
Number of subjects: 30
Study 23680830 — intervention group
Group type: EXPERIMENTAL
Intervention: Coflex interlaminar stabilization
Number of subjects: 322
Study 23680830 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral spinal fusion with spinal instrumentation
Number of subjects: 322
Study 21959663 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior positioning splint therapy (group I)
Number of subjects: 60
Study 21959663 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (group II)
Number of subjects: 60
Study 21959663 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy in addition to splint therapy (group III)
Number of subjects: 60
Study 21959663 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group I and group II
Number of subjects: 60
Study 21959663 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group II and group III
Number of subjects: 60
Study 21959663 — intervention group
Group type: COMPARATOR
Intervention: Overall sample
Number of subjects: 60
Study 18303526 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics, nitrates, inotropes (dobutamine, milrinone)
Number of subjects: 0
Study 18303526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide, Tolvaptan, Levosimedan
Number of subjects: 0
Study 18303526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive drugs
Number of subjects: 0
Study 15902179 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached pushing
Number of subjects: 128
Study 15902179 — intervention group
Group type: COMPARATOR
Intervention: Uncoached pushing
Number of subjects: 128